17.24
-3.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sarepta Therapeutics
From its filings with the US Securities and Exchange Commission
Sarepta Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SRPT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.20bn and a net loss of $713.4m. At that date it held total assets of $3.35bn and shareholders' equity of $1.14bn.
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD. We are also developing potential therapeutic candidates through our partnered program with Arrowhead for the treatment of Facioscapulohumeral muscular dystrophy ("FSHD"), myotonic dystrophy type 1 (“DM1”), Spinocerebellar ataxia ("SCA"), Idiopathic Pulmonary Fibrosis ("IPF"), Huntington's disease and other neuromuscular and skeletal diseases.
To date, we have developed and commercialized the following four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen) Injection (“EXONDYS 51”), VYONDYS 53 (golodirsen) Injection (“VYONDYS 53”), AMONDYS 45 (casimersen) Injection (“AMONDYS 45”), and ELEVIDYS. Each of these approved products, and the indications for which they have been approved for, is described under the heading “Our Commercial Products” in this Item 1.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Jun 1997
- Employees
- 835
- Website
- sarepta.com ↗
- Head office
- 215 FIRST STREET, CAMBRIDGE, MA, 02142
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. M. Kathleen BehrensIndependent Chairwoman of the Board$616,953
- Mr. Ian EstepanPresident, Chief Operating Officer$2.8m
- Mr. Douglas IngramChief Executive Officer, since 2017$2.0m
- Mr. Ryan WongChief Financial Officer, Executive Vice President
- Dr. Louise Rodino-KlapacPresident - Research and Development and Technical Operations$2.7m
- Ms. Cristin RothfussExecutive Vice President, General Counsel, Corporate Secretary
- Mr. Dallan MurrayExecutive Vice President, Chief Customer Officer$2.7m
- Mr. Richard BarryIndependent Director$593,200
- Dr. Kathryn BoorIndependent Director$562,885
- Mr. Michael ChambersIndependent Director$554,638
- Ms. Deirdre ConnellyIndependent Director$730,975
- Dr. Stephen MayoIndependent Director$567,138
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 30
- Social
- 42
- Governance
- 43
- Direct emissions (scope 1)
- 3,428 t
- Energy emissions (scope 2)
- 5,000 t
- Women in the workforce
- 57%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sarepta Therapeutics Inc has a strong portfolio of innovative gene therapy products, positioning the company as a leader in the biotechnology industry. It has achieved significant success in developing treatments for rare genetic diseases, which provides a unique competitive advantage.
- The company possesses a robust intellectual property portfolio, offering strong protection and exclusivity for its therapies. This enables Sarepta Therapeutics to maintain a dominant position in the market and capitalize on its technological advancements.
Weaknesses
- Sarepta Therapeutics heavily relies on a few key products, which makes the company vulnerable to any potential setbacks or failures associated with these particular therapies. This concentration of products poses a risk to the business's overall stability and future growth.
- The company also faces challenges in terms of manufacturing scalability and production capacity. Scaling up production while maintaining strict quality control standards is crucial for Sarepta Therapeutics to meet growing market demand, but it requires significant investments and expertise.
Opportunities
- The increasing prevalence of genetic disorders and the growing recognition of gene therapies as a viable treatment option present significant opportunities for Sarepta Therapeutics. Expanding its product offerings and partnering with healthcare organizations can help the company tap into new markets and broaden its patient reach.
- Collaborations and strategic alliances with research institutions and pharmaceutical companies provide Sarepta Therapeutics with the chance to leverage external expertise, resources, and knowledge to accelerate product development and enhance its competitive position.
Threats
- Sarepta Therapeutics operates in a highly regulated industry, facing challenges and uncertainties related to regulatory approvals and compliance. Any delays or denials in obtaining necessary approvals for its products can significantly impact the company's financial performance and market competitiveness.
- The competitive landscape is intensifying as more companies enter the gene therapy market. Sarepta Therapeutics is prone to competition from existing and emerging biotechnology firms, making it crucial for the company to continuously innovate and protect its intellectual property to maintain its market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.